Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics
  • Log in
Advertisement

Main menu

  • Home
  • About Us
    • AACR Journals
    • Subscriptions
    • Permissions & Reprints
    • Advertising
  • Article Collections
    • Focus Sections
    • Journal Collections
    • Topical Collections
    • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
  • Alerts
    • Table of Contents
    • Editors' Picks
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Log in

Search

  • Advanced search
American Association for Cancer Research

American Association for Cancer Research

Advanced Search

  • Home
  • About Us
    • AACR Journals
    • Subscriptions
    • Permissions & Reprints
    • Advertising
  • Article Collections
    • Focus Sections
    • Journal Collections
    • Topical Collections
    • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
  • Alerts
    • Table of Contents
    • Editors' Picks
  • Visit AACR on Facebook
  • Follow AACR on Twitter
  • Visit AACR on LinkedIn
  • Visit AACR on YouTube

About the Cover

02 Sep 2016; Volume 4,Issue 9

Cover image

Cover image expansion

About the Cover
Intensive research into the intertwined relationship of the immune system with tumors is yielding new therapies that rely on managing a patient's immune system to promote long-term tumor destruction. Melanoma is the poster child for immunotherapies, with many clinical trials first tested in patients with this tumor. The Rosenberg lab has been treating patients with improved versions of the patient's own cells that recognize and kill melanoma cells. Their latest study identifies T-cell receptors (TCRs) that recognize a patient's tumor antigens based on the frequency of TCR usage among the T cells present in the patient's tumors. The original micrograph (right) depicts a melanin-filled antigen-presenting cell (brown) surrounded by T cells, in the midst of a melanoma tumor. Read more in the article by Pasetto et al., starting on page 734 of this issue. The micrograph (right) is from the Steven Rosenberg laboratory. Artwork is by Lewis Long.

Back to top

In this issue

Cancer Immunology Research: 4 (9)
Cancer Immunology
Vol. 4, Issue 9
2 Sep 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  Sign up for alerts

Jump to

  • What We're Reading
  • Book Review
  • In the Spotlight
  • Masters of Immunology
  • Cancer Immunology Miniatures
  • Research Articles
  • Top Topics
  • Most Cited
  • Most Read
Loading
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   YouTube   RSS

Article Collections

  • Focus Selections
  • Topical Collections
  • "Best of" Collection

Info for:

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

AACR Journals

  • About AACR Journals
  • 3rd Party Permissions & Reprints

AACR logo

Copyright © 2018 by the American Association for Cancer Research.